文献速递肝病

肝硬化再入院与医院再入院减少计划:隐藏的挑战

Readmissions for Cirrhosis Within the Healthcare Readmissions Reduction Program: A Hidden Challenge.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

本文为社论,讨论肝硬化患者在《医院再入院减少计划》(HRRP)背景下的再入院问题及不断演变的照护模式。文章指出,尽管肝硬化患者再入院及其他不良结局风险高,但常被排除在HRRP等大型政策决策之外。

要点

  • 肝硬化患者再入院及其他不良结局风险高。
  • 肝硬化患者常被排除在HRRP等大型政策决策之外。
  • 社论在HRRP及演变照护模式背景下讨论肝硬化再入院。

核心结论

  • 肝硬化患者再入院风险高,却常被排除在HRRP等大型政策决策之外。

研究设计与样本

  • 社论,讨论肝硬化患者再入院与HRRP及演变照护模式的关系。

主要发现

  • HRRP实施后充血性心力衰竭、肺炎和心肌梗死再入院显著减少。
  • 肝硬化患者常被排除在HRRP等大型政策决策之外。
  • 肝硬化患者再入院及其他不良结局风险高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the passage of the Affordable Care Act, the Healthcare Readmissions Reduction Program (HRRP) was implemented, leading to significant reductions in readmissions for congestive heart failure, pneumonia, and myocardial infarction. Patients with cirrhosis have a complex and difficult to manage underlying disease process and are often left out of large policy decisions such as the HRRP although they represent a population at high risk for readmission and other negative outcomes. In this editorial, hospital readmissions in patients with cirrhosis are discussed in the context of the HRRP and evolving models of care.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Henry Z. Readmissions for Cirrhosis Within the Healthcare Readmissions Reduction Program: A Hidden Challenge. Am J Gastroenterol. 2019. PMID: 31449155. doi:10.14309/ajg.0000000000000368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。